- Featured Product
- KD/KO Validated
TDP-43 Polyclonal antibody
TDP-43 Polyclonal Antibody for FC, IF, IHC, WB, ELISA
Cat No : 10782-2-AP
|Positive WB detected in||SH-SY5Y cells, HeLa cells, C2C12 cells, Neuro-2a cells|
|Positive IHC detected in||human gliomas tissue, human brain (FTLD-U) tissue, mouse brain tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive IF detected in||HeLa cells|
|Positive FC detected in||HeLa cells|
|Western Blot (WB)||WB : 1:2000-1:10000|
|Immunohistochemistry (IHC)||IHC : 1:2000-1:8000|
|Immunofluorescence (IF)||IF : 1:3000-1:12000|
|Sample-dependent, check data in validation data gallery|
10782-2-AP targets TDP-43 in WB, RIP, IP, IHC, IF, IEM, FC, CoIP, ChIP, ELISA applications and shows reactivity with human, mouse, rat, zebrafish samples.
|Tested Applications||FC, IF, IHC, WB, ELISA|
|Cited Applications||ChIP, CoIP, ELISA, IEM, IF, IHC, IP, RIP, WB|
|Tested Reactivity||human, mouse, rat, zebrafish|
|Cited Reactivity||human, mouse, rat, chicken, horse, Yeast, seal, monkey, zebrafish, hamster|
|Immunogen||fusion protein 种属同源性预测|
|Host / Isotype||Rabbit / IgG|
|Full Name||TAR DNA binding protein|
|Synonyms||ALS10, TAR DNA binding protein, TAR DNA binding protein 43, TARDBP, TDP 43, TDP43, TDP-43|
|Calculated molecular weight||43 kDa|
|Observed molecular weight||44 kDa|
|GenBank accession number||BC001487|
|Gene ID (NCBI)||23435|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
The TARDBP gene encodes the TDP-43 protein, initially found to repress HIV-1 transcription by binding TAR DNA. TDP-43 has since been shown to bind RNA as well as DNA, and have multiple functions in transcriptional repression, translational regulation and pre-mRNA splicing. For instance, it is reported to regulate alternate splicing of the CTFR gene. In 2006 Neumann et al. found that hyperphosphorylated, ubiquitinated and/or cleaved forms of TDP-43, collectively known as pathological TDP-43, play a major role in the disease mechanisms of ubiquitin-positive, tau- and alpha-synuclein-negative frontotemporal dementia (FTLD-U) and in amyotrophic lateral sclerosis (ALS). Proteintech's 10782-2-AP antibody is a rabbit polyclonal antibody recognizing N-terminal TDP-43. It recognizes the intact 43 kDa protein as well as all posttranslationally modified and truncated forms in multiple applications. Various forms of TDP-43 exist, including 18-35 kDa of cleaved C-terminal fragments, 45-50 kDa phospho-protein, 55 kDa glycosylated form, 75 kDa hyperphosphorylated form, and 90-300 kDa cross-linked form. (17023659, 19823856, 21666678, 22193176) Recently TDP-43 has been reported to be overexpressed in triple negative breast cancer (TNBC) and it may be a potential target for TNBC diagnosis and drug design. (29581274)
A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study.
Disruption of ER ion homeostasis maintained by an ER anion channel CLCC1 contributes to ALS-like pathologies
MIR-NATs repress MAPT translation and aid proteostasis in neurodegeneration.
Neurotoxic microglia promote TDP-43 proteinopathy in progranulin deficiency.
TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A.
TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A.